[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftZSuzCadCQvO5OIehbkLJQ2s0oRucePe88GqE7Bpe2o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":34,"phaseBuckets":65,"rows":72},"Boston University",[4,6],"Boston University Charles River Campus",414,false,87,11,9700624,14,342,[15,18,20,23,25,27,30,32],{"name":16,"count":17},"HIV",24,{"name":19,"count":12},"Depression",{"name":21,"count":22},"HIV Infections",9,{"name":24,"count":22},"Parkinson Disease",{"name":26,"count":22},"Cardiovascular Diseases",{"name":28,"count":29},"Vitamin D Deficiency",8,{"name":31,"count":29},"Anxiety",{"name":33,"count":29},"Stroke",[35,40,45,50,55,60],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03560960","Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease","2026-11","Pramlintide challenge test",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06385275","The Role of Vitamin K on Knee Osteoarthritis Outcomes","2026-12","Vitamin K1 500 µg",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06757075","Management of Postoperative Discomfort in Young Children Following Dental Rehabilitation Under General Anesthesia","2027-03","Ibuprofen",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05683223","Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety","2027-04-01","Sertraline",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03828201","Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","2027-05","Delamanid",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05381597","5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer","2027-06","Combination cream of 5-fluorouracil and calcipotriene",[66,67,68,69,70,71],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[73,98,116,139,157,208,231,253,271,289,312,330,348,370,392,417,442,460,485,503,528,546,574,592,617,635,653,680,709,727,753,779,797,822,911,929,947,965,989,1015,1048,1066,1084,1111,1129,1154,1181,1199,1224,1248,1273,1297,1321,1348,1372,1390,1416,1434,1459,1477,1503,1526,1550,1576,1601,1624,1650,1676,1701,1728,1746,1771,1811,1840,1877,1911,1938,1961,1989,2007,2025,2048,2075,2099,2122,2143,2167,2193,2211,2235],{"intervention":49,"totalTrials":74,"cells":75},1,{"EARLY_PHASE1":76,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":96},{"trials":77,"activeCount":78},[],0,{"trials":80,"activeCount":78},[],{"trials":82,"activeCount":78},[],{"trials":84,"activeCount":78},[],{"trials":86,"activeCount":74,"soonestReadout":48},[87],{"nctId":46,"briefTitle":47,"status":88,"phases":89,"primaryCompletion":48,"completion":48,"start":90,"enrollment":91,"conditions":92,"interventions":94},"RECRUITING",[70],"2025-04-16",75,[93],"Pain, Postoperative",[49,95],"Acetominophen",{"trials":97,"activeCount":78},[],{"intervention":95,"totalTrials":74,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":114},{"trials":101,"activeCount":78},[],{"trials":103,"activeCount":78},[],{"trials":105,"activeCount":78},[],{"trials":107,"activeCount":78},[],{"trials":109,"activeCount":74,"soonestReadout":48},[110],{"nctId":46,"briefTitle":47,"status":88,"phases":111,"primaryCompletion":48,"completion":48,"start":90,"enrollment":91,"conditions":112,"interventions":113},[70],[93],[49,95],{"trials":115,"activeCount":78},[],{"intervention":64,"totalTrials":74,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":135,"NA":137},{"trials":119,"activeCount":78},[],{"trials":121,"activeCount":78},[],{"trials":123,"activeCount":78},[],{"trials":125,"activeCount":74,"soonestReadout":63},[126],{"nctId":61,"briefTitle":62,"status":88,"phases":127,"primaryCompletion":63,"completion":63,"start":128,"enrollment":129,"conditions":130,"interventions":133},[68,69],"2022-10-15",200,[131,132],"Superficial Basal Cell Carcinoma","Squamous Cell Carcinoma in Situ",[64,134],"5-fluorouracil cream",{"trials":136,"activeCount":78},[],{"trials":138,"activeCount":78},[],{"intervention":134,"totalTrials":74,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":153,"NA":155},{"trials":142,"activeCount":78},[],{"trials":144,"activeCount":78},[],{"trials":146,"activeCount":78},[],{"trials":148,"activeCount":74,"soonestReadout":63},[149],{"nctId":61,"briefTitle":62,"status":88,"phases":150,"primaryCompletion":63,"completion":63,"start":128,"enrollment":129,"conditions":151,"interventions":152},[68,69],[131,132],[64,134],{"trials":154,"activeCount":78},[],{"trials":156,"activeCount":78},[],{"intervention":158,"totalTrials":159,"cells":160},"Levofloxacin",3,{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":189,"PHASE4":204,"NA":206},{"trials":162,"activeCount":78},[],{"trials":164,"activeCount":78},[],{"trials":166,"activeCount":74,"soonestReadout":58},[167,178],{"nctId":56,"briefTitle":57,"status":168,"phases":169,"primaryCompletion":58,"completion":58,"start":170,"enrollment":171,"conditions":172,"interventions":174},"ACTIVE_NOT_RECRUITING",[68],"2022-06-07",271,[173],"Tuberculosis, Multidrug-Resistant",[59,158,175,176,177],"Bedaquiline","Clofazimine","Linezolid",{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"NCT01918397","Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB","COMPLETED",[68],"2022-03-29","2015-01",111,[173],[158,188],"Optimized background regimen",{"trials":190,"activeCount":78},[191],{"nctId":192,"briefTitle":193,"status":194,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"enrollment":78,"conditions":199,"interventions":201},"NCT02975570","Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","WITHDRAWN",[69],"2021-08","2022-08","2017-08",[200],"Tuberculosis Multi Drug Resistant Active",[59,177,158,202,203],"Pyrazinamide","WHO MDR-TB regimen",{"trials":205,"activeCount":78},[],{"trials":207,"activeCount":78},[],{"intervention":59,"totalTrials":209,"cells":210},2,{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":221,"PHASE4":227,"NA":229},{"trials":212,"activeCount":78},[],{"trials":214,"activeCount":78},[],{"trials":216,"activeCount":74,"soonestReadout":58},[217],{"nctId":56,"briefTitle":57,"status":168,"phases":218,"primaryCompletion":58,"completion":58,"start":170,"enrollment":171,"conditions":219,"interventions":220},[68],[173],[59,158,175,176,177],{"trials":222,"activeCount":78},[223],{"nctId":192,"briefTitle":193,"status":194,"phases":224,"primaryCompletion":196,"completion":197,"start":198,"enrollment":78,"conditions":225,"interventions":226},[69],[200],[59,177,158,202,203],{"trials":228,"activeCount":78},[],{"trials":230,"activeCount":78},[],{"intervention":177,"totalTrials":209,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":243,"PHASE4":249,"NA":251},{"trials":234,"activeCount":78},[],{"trials":236,"activeCount":78},[],{"trials":238,"activeCount":74,"soonestReadout":58},[239],{"nctId":56,"briefTitle":57,"status":168,"phases":240,"primaryCompletion":58,"completion":58,"start":170,"enrollment":171,"conditions":241,"interventions":242},[68],[173],[59,158,175,176,177],{"trials":244,"activeCount":78},[245],{"nctId":192,"briefTitle":193,"status":194,"phases":246,"primaryCompletion":196,"completion":197,"start":198,"enrollment":78,"conditions":247,"interventions":248},[69],[200],[59,177,158,202,203],{"trials":250,"activeCount":78},[],{"trials":252,"activeCount":78},[],{"intervention":175,"totalTrials":74,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":256,"activeCount":78},[],{"trials":258,"activeCount":78},[],{"trials":260,"activeCount":74,"soonestReadout":58},[261],{"nctId":56,"briefTitle":57,"status":168,"phases":262,"primaryCompletion":58,"completion":58,"start":170,"enrollment":171,"conditions":263,"interventions":264},[68],[173],[59,158,175,176,177],{"trials":266,"activeCount":78},[],{"trials":268,"activeCount":78},[],{"trials":270,"activeCount":78},[],{"intervention":176,"totalTrials":74,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":283,"PHASE4":285,"NA":287},{"trials":274,"activeCount":78},[],{"trials":276,"activeCount":78},[],{"trials":278,"activeCount":74,"soonestReadout":58},[279],{"nctId":56,"briefTitle":57,"status":168,"phases":280,"primaryCompletion":58,"completion":58,"start":170,"enrollment":171,"conditions":281,"interventions":282},[68],[173],[59,158,175,176,177],{"trials":284,"activeCount":78},[],{"trials":286,"activeCount":78},[],{"trials":288,"activeCount":78},[],{"intervention":44,"totalTrials":74,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":292,"activeCount":78},[],{"trials":294,"activeCount":78},[],{"trials":296,"activeCount":74,"soonestReadout":43},[297],{"nctId":41,"briefTitle":42,"status":88,"phases":298,"primaryCompletion":43,"completion":43,"start":299,"enrollment":300,"conditions":301,"interventions":303},[67,68],"2025-06-03",55,[302],"Osteo Arthritis Knee",[44,304,305],"K1 1000 µg","Vitamin K2 (MK-7) 300 µg",{"trials":307,"activeCount":78},[],{"trials":309,"activeCount":78},[],{"trials":311,"activeCount":78},[],{"intervention":304,"totalTrials":74,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":315,"activeCount":78},[],{"trials":317,"activeCount":78},[],{"trials":319,"activeCount":74,"soonestReadout":43},[320],{"nctId":41,"briefTitle":42,"status":88,"phases":321,"primaryCompletion":43,"completion":43,"start":299,"enrollment":300,"conditions":322,"interventions":323},[67,68],[302],[44,304,305],{"trials":325,"activeCount":78},[],{"trials":327,"activeCount":78},[],{"trials":329,"activeCount":78},[],{"intervention":305,"totalTrials":74,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":333,"activeCount":78},[],{"trials":335,"activeCount":78},[],{"trials":337,"activeCount":74,"soonestReadout":43},[338],{"nctId":41,"briefTitle":42,"status":88,"phases":339,"primaryCompletion":43,"completion":43,"start":299,"enrollment":300,"conditions":340,"interventions":341},[67,68],[302],[44,304,305],{"trials":343,"activeCount":78},[],{"trials":345,"activeCount":78},[],{"trials":347,"activeCount":78},[],{"intervention":39,"totalTrials":74,"cells":349},{"EARLY_PHASE1":350,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":368},{"trials":351,"activeCount":74,"soonestReadout":38},[352],{"nctId":36,"briefTitle":37,"status":168,"phases":353,"primaryCompletion":38,"completion":38,"start":354,"enrollment":355,"conditions":356,"interventions":359},[66],"2020-02-04",57,[357,358],"Alzheimer Disease","Mild Cognitive Impairment",[39],{"trials":361,"activeCount":78},[],{"trials":363,"activeCount":78},[],{"trials":365,"activeCount":78},[],{"trials":367,"activeCount":78},[],{"trials":369,"activeCount":78},[],{"intervention":54,"totalTrials":74,"cells":371},{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":373,"activeCount":78},[],{"trials":375,"activeCount":78},[],{"trials":377,"activeCount":78},[],{"trials":379,"activeCount":78},[],{"trials":381,"activeCount":78},[],{"trials":383,"activeCount":74,"soonestReadout":53},[384],{"nctId":51,"briefTitle":52,"status":88,"phases":385,"primaryCompletion":53,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":391},[71],"2027-06-30","2023-05-26",240,[390],"Social Anxiety Disorder",[54],{"intervention":393,"totalTrials":74,"cells":394},"Topiramate",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":415},{"trials":396,"activeCount":78},[],{"trials":398,"activeCount":78},[],{"trials":400,"activeCount":78},[],{"trials":402,"activeCount":78},[],{"trials":404,"activeCount":78},[405],{"nctId":406,"briefTitle":407,"status":181,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":414},"NCT00329407","The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects",[70],"2008-06","2003-09",10,[413],"Alcoholism",[393],{"trials":416,"activeCount":78},[],{"intervention":418,"totalTrials":74,"cells":419},"Vicodin",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":440},{"trials":421,"activeCount":78},[],{"trials":423,"activeCount":78},[],{"trials":425,"activeCount":78},[],{"trials":427,"activeCount":78},[],{"trials":429,"activeCount":78},[430],{"nctId":431,"briefTitle":432,"status":194,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":78,"conditions":436,"interventions":438},"NCT04008043","Pilot Study: Effect of Dexamethasone vs Vicodin in Reducing Post-operative Pain",[70],"2021-05","2020-02",[437],"Oral Surgery",[418,439],"Dexamethasone",{"trials":441,"activeCount":78},[],{"intervention":439,"totalTrials":74,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":458},{"trials":445,"activeCount":78},[],{"trials":447,"activeCount":78},[],{"trials":449,"activeCount":78},[],{"trials":451,"activeCount":78},[],{"trials":453,"activeCount":78},[454],{"nctId":431,"briefTitle":432,"status":194,"phases":455,"primaryCompletion":434,"completion":434,"start":435,"enrollment":78,"conditions":456,"interventions":457},[70],[437],[418,439],{"trials":459,"activeCount":78},[],{"intervention":461,"totalTrials":74,"cells":462},"lidocaine",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":483},{"trials":464,"activeCount":78},[],{"trials":466,"activeCount":78},[],{"trials":468,"activeCount":78},[],{"trials":470,"activeCount":78},[],{"trials":472,"activeCount":78},[473],{"nctId":474,"briefTitle":475,"status":194,"phases":476,"primaryCompletion":477,"completion":477,"start":478,"enrollment":78,"conditions":479,"interventions":481},"NCT03318952","Articaine vs Lidocaine for Pediatric Dental Procedures",[70],"2023-06","2022-09",[480,93],"Anesthesia, Dental",[461,482],"articaine",{"trials":484,"activeCount":78},[],{"intervention":482,"totalTrials":74,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":501},{"trials":488,"activeCount":78},[],{"trials":490,"activeCount":78},[],{"trials":492,"activeCount":78},[],{"trials":494,"activeCount":78},[],{"trials":496,"activeCount":78},[497],{"nctId":474,"briefTitle":475,"status":194,"phases":498,"primaryCompletion":477,"completion":477,"start":478,"enrollment":78,"conditions":499,"interventions":500},[70],[480,93],[461,482],{"trials":502,"activeCount":78},[],{"intervention":504,"totalTrials":74,"cells":505},"Bupivacaine Extended Release Liposome",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":514,"NA":526},{"trials":507,"activeCount":78},[],{"trials":509,"activeCount":78},[],{"trials":511,"activeCount":78},[],{"trials":513,"activeCount":78},[],{"trials":515,"activeCount":78},[516],{"nctId":517,"briefTitle":518,"status":194,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":78,"conditions":522,"interventions":524},"NCT03318757","Bupivacaine Liposomal Injectable Suspension, Pain and Narcotic Use After Elective Orthognathic Surgery",[70],"2021-12","2020-09",[523],"Orthognathic Surgery",[504,525],"Bupivacaine HCl",{"trials":527,"activeCount":78},[],{"intervention":525,"totalTrials":74,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":544},{"trials":531,"activeCount":78},[],{"trials":533,"activeCount":78},[],{"trials":535,"activeCount":78},[],{"trials":537,"activeCount":78},[],{"trials":539,"activeCount":78},[540],{"nctId":517,"briefTitle":518,"status":194,"phases":541,"primaryCompletion":520,"completion":520,"start":521,"enrollment":78,"conditions":542,"interventions":543},[70],[523],[504,525],{"trials":545,"activeCount":78},[],{"intervention":547,"totalTrials":74,"cells":548},"Sildenafil citrate",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":572},{"trials":550,"activeCount":78},[],{"trials":552,"activeCount":78},[],{"trials":554,"activeCount":78},[],{"trials":556,"activeCount":78},[],{"trials":558,"activeCount":78},[559],{"nctId":560,"briefTitle":561,"status":181,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":570},"NCT00512707","Effect of Testosterone in Men With Erectile Dysfunction",[70],"2010-05","2006-11",140,[567,568,569],"Erectile Dysfunction","Testosterone Deficiency","Diabetes",[547,571],"Testosterone gel",{"trials":573,"activeCount":78},[],{"intervention":571,"totalTrials":74,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":590},{"trials":577,"activeCount":78},[],{"trials":579,"activeCount":78},[],{"trials":581,"activeCount":78},[],{"trials":583,"activeCount":78},[],{"trials":585,"activeCount":78},[586],{"nctId":560,"briefTitle":561,"status":181,"phases":587,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":588,"interventions":589},[70],[567,568,569],[547,571],{"trials":591,"activeCount":78},[],{"intervention":593,"totalTrials":74,"cells":594},"Beta-blocker strategy",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":603,"NA":615},{"trials":596,"activeCount":78},[],{"trials":598,"activeCount":78},[],{"trials":600,"activeCount":78},[],{"trials":602,"activeCount":78},[],{"trials":604,"activeCount":78},[605],{"nctId":606,"briefTitle":607,"status":194,"phases":608,"primaryCompletion":609,"completion":609,"start":520,"enrollment":78,"conditions":610,"interventions":612},"NCT04234477","Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)",[70],"2022-06",[611],"Atrial Fibrillation",[593,613,614],"Calcium channel blocker strategy","Physician preference strategy",{"trials":616,"activeCount":78},[],{"intervention":613,"totalTrials":74,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":633},{"trials":620,"activeCount":78},[],{"trials":622,"activeCount":78},[],{"trials":624,"activeCount":78},[],{"trials":626,"activeCount":78},[],{"trials":628,"activeCount":78},[629],{"nctId":606,"briefTitle":607,"status":194,"phases":630,"primaryCompletion":609,"completion":609,"start":520,"enrollment":78,"conditions":631,"interventions":632},[70],[611],[593,613,614],{"trials":634,"activeCount":78},[],{"intervention":614,"totalTrials":74,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":651},{"trials":638,"activeCount":78},[],{"trials":640,"activeCount":78},[],{"trials":642,"activeCount":78},[],{"trials":644,"activeCount":78},[],{"trials":646,"activeCount":78},[647],{"nctId":606,"briefTitle":607,"status":194,"phases":648,"primaryCompletion":609,"completion":609,"start":520,"enrollment":78,"conditions":649,"interventions":650},[70],[611],[593,613,614],{"trials":652,"activeCount":78},[],{"intervention":654,"totalTrials":74,"cells":655},"Dapagliflozin",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":664,"NA":678},{"trials":657,"activeCount":78},[],{"trials":659,"activeCount":78},[],{"trials":661,"activeCount":78},[],{"trials":663,"activeCount":78},[],{"trials":665,"activeCount":78},[666],{"nctId":667,"briefTitle":668,"status":669,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":673,"conditions":674,"interventions":677},"NCT05139914","Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes","TERMINATED",[70],"2025-02-04","2022-05-31",4,[675,676],"Diabetes Mellitus, Type 2","Endothelial Dysfunction",[654],{"trials":679,"activeCount":78},[],{"intervention":681,"totalTrials":74,"cells":682},"Oral naltrexone",{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":707},{"trials":684,"activeCount":78},[],{"trials":686,"activeCount":78},[],{"trials":688,"activeCount":78},[],{"trials":690,"activeCount":78},[],{"trials":692,"activeCount":78},[693],{"nctId":694,"briefTitle":695,"status":181,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":705},"NCT02478489","Alcohol Disorder hOsPital Treatment Trial",[70],"2020-07","2020-10","2016-06",248,[702,703,704],"Heavy Drinking","Alcohol Dependence","Alcohol Use Disorder",[681,706],"Extended-release injectable naltrexone",{"trials":708,"activeCount":78},[],{"intervention":706,"totalTrials":74,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":725},{"trials":712,"activeCount":78},[],{"trials":714,"activeCount":78},[],{"trials":716,"activeCount":78},[],{"trials":718,"activeCount":78},[],{"trials":720,"activeCount":78},[721],{"nctId":694,"briefTitle":695,"status":181,"phases":722,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":723,"interventions":724},[70],[702,703,704],[681,706],{"trials":726,"activeCount":78},[],{"intervention":728,"totalTrials":74,"cells":729},"Ranolazine",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":751},{"trials":731,"activeCount":78},[],{"trials":733,"activeCount":78},[],{"trials":735,"activeCount":78},[],{"trials":737,"activeCount":78},[],{"trials":739,"activeCount":78},[740],{"nctId":741,"briefTitle":742,"status":181,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":411,"conditions":747,"interventions":750},"NCT02133352","Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction",[70],"2013-05","2014-05","2011-07",[748,749],"Pulmonary Hypertension","Diastolic Left Ventricular Dysfunction",[728],{"trials":752,"activeCount":78},[],{"intervention":754,"totalTrials":74,"cells":755},"Crisaborole 2%",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":777},{"trials":757,"activeCount":78},[],{"trials":759,"activeCount":78},[],{"trials":761,"activeCount":78},[],{"trials":763,"activeCount":78},[],{"trials":765,"activeCount":78},[766],{"nctId":767,"briefTitle":768,"status":669,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT05200403","Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis",[70],"2024-02-15","2022-07-26",72,[774],"Atopic Dermatitis",[754,776],"Vehicle treatment",{"trials":778,"activeCount":78},[],{"intervention":776,"totalTrials":74,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":795},{"trials":782,"activeCount":78},[],{"trials":784,"activeCount":78},[],{"trials":786,"activeCount":78},[],{"trials":788,"activeCount":78},[],{"trials":790,"activeCount":78},[791],{"nctId":767,"briefTitle":768,"status":669,"phases":792,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":793,"interventions":794},[70],[774],[754,776],{"trials":796,"activeCount":78},[],{"intervention":798,"totalTrials":74,"cells":799},"Levetiracetam",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":820},{"trials":801,"activeCount":78},[],{"trials":803,"activeCount":78},[],{"trials":805,"activeCount":78},[],{"trials":807,"activeCount":78},[],{"trials":809,"activeCount":78},[810],{"nctId":811,"briefTitle":812,"status":181,"phases":813,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":819},"NCT00325182","The Effects of Levetiracetam on Alcohol Dependent Subjects",[70],"2007-01","2009-10","2006-01",40,[413],[798],{"trials":821,"activeCount":78},[],{"intervention":823,"totalTrials":824,"cells":825},"D-cycloserine",7,{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":885,"PHASE4":907,"NA":909},{"trials":827,"activeCount":78},[],{"trials":829,"activeCount":78},[],{"trials":831,"activeCount":78},[832,843,852,864,875],{"nctId":833,"briefTitle":834,"status":194,"phases":835,"primaryCompletion":836,"completion":836,"start":837,"enrollment":78,"conditions":838,"interventions":840},"NCT04035603","Multimodal Cue Exposure Therapy for Smoking Cessation",[68],"2021-01-31","2020-10-01",[839],"Smoking Cessation",[841,842],"D-Cycloserine","Open phase smoking cessation pharmacotherapy that proceeds the randomization phase",{"nctId":844,"briefTitle":845,"status":194,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":78,"conditions":849,"interventions":851},"NCT00827281","D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)",[68],"2015-07-15","2008-08",[850],"Smokers",[823],{"nctId":853,"briefTitle":854,"status":855,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":862},"NCT02983734","D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)","UNKNOWN",[68],"2019-09","2015-10",56,[861],"Gulf War Illness",[823,863],"Placebos",{"nctId":865,"briefTitle":866,"status":181,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT00790868","Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder",[68],"2014-08","2008-04",180,[872],"Panic Disorder",[874],"d-cycloserine",{"nctId":876,"briefTitle":877,"status":669,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":884},"NCT00430573","Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use",[68],"2009-06","2007-02",15,[883],"Substance-Related Disorders",[823],{"trials":886,"activeCount":78},[887,898],{"nctId":888,"briefTitle":889,"status":194,"phases":890,"primaryCompletion":891,"completion":892,"start":893,"enrollment":78,"conditions":894,"interventions":896},"NCT03216356","Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD",[68,69],"2023-12","2024-12","2016-09",[895],"PTSD",[841,897],"Study Pill",{"nctId":899,"briefTitle":900,"status":181,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":906},"NCT00515879","Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia",[69],"2011-12","2007-12",169,[390],[823],{"trials":908,"activeCount":78},[],{"trials":910,"activeCount":78},[],{"intervention":897,"totalTrials":74,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":925,"NA":927},{"trials":914,"activeCount":78},[],{"trials":916,"activeCount":78},[],{"trials":918,"activeCount":78},[],{"trials":920,"activeCount":78},[921],{"nctId":888,"briefTitle":889,"status":194,"phases":922,"primaryCompletion":891,"completion":892,"start":893,"enrollment":78,"conditions":923,"interventions":924},[68,69],[895],[841,897],{"trials":926,"activeCount":78},[],{"trials":928,"activeCount":78},[],{"intervention":202,"totalTrials":74,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":943,"NA":945},{"trials":932,"activeCount":78},[],{"trials":934,"activeCount":78},[],{"trials":936,"activeCount":78},[],{"trials":938,"activeCount":78},[939],{"nctId":192,"briefTitle":193,"status":194,"phases":940,"primaryCompletion":196,"completion":197,"start":198,"enrollment":78,"conditions":941,"interventions":942},[69],[200],[59,177,158,202,203],{"trials":944,"activeCount":78},[],{"trials":946,"activeCount":78},[],{"intervention":203,"totalTrials":74,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":961,"NA":963},{"trials":950,"activeCount":78},[],{"trials":952,"activeCount":78},[],{"trials":954,"activeCount":78},[],{"trials":956,"activeCount":78},[957],{"nctId":192,"briefTitle":193,"status":194,"phases":958,"primaryCompletion":196,"completion":197,"start":198,"enrollment":78,"conditions":959,"interventions":960},[69],[200],[59,177,158,202,203],{"trials":962,"activeCount":78},[],{"trials":964,"activeCount":78},[],{"intervention":966,"totalTrials":74,"cells":967},"Fluoxetine",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":985,"NA":987},{"trials":969,"activeCount":78},[],{"trials":971,"activeCount":78},[],{"trials":973,"activeCount":78},[],{"trials":975,"activeCount":78},[976],{"nctId":977,"briefTitle":978,"status":181,"phases":979,"completion":980,"start":981,"conditions":982,"interventions":984},"NCT00000379","Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)",[69],"2003-12","1999-01",[983],"Stress Disorders, Post-Traumatic",[966],{"trials":986,"activeCount":78},[],{"trials":988,"activeCount":78},[],{"intervention":990,"totalTrials":74,"cells":991},"diflunisal",{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":996,"PHASE3":998,"PHASE4":1011,"NA":1013},{"trials":993,"activeCount":78},[],{"trials":995,"activeCount":78},[],{"trials":997,"activeCount":78},[],{"trials":999,"activeCount":78},[1000],{"nctId":1001,"briefTitle":1002,"status":181,"phases":1003,"primaryCompletion":1004,"completion":1004,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1010},"NCT00294671","The Effect of Diflunisal on Familial Amyloidosis",[68,69],"2012-12","2006-02",130,[1008,1009],"Familial Amyloid Polyneuropathy","Familial Amyloidosis",[990],{"trials":1012,"activeCount":78},[],{"trials":1014,"activeCount":78},[],{"intervention":1016,"totalTrials":209,"cells":1017},"sodium 2,2 dimethylbutyrate",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1019,"activeCount":78},[],{"trials":1021,"activeCount":78},[],{"trials":1023,"activeCount":78},[1024,1033],{"nctId":1025,"briefTitle":1026,"status":181,"phases":1027,"primaryCompletion":1028,"completion":1004,"start":1029,"enrollment":411,"conditions":1030,"interventions":1032},"NCT01609595","Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand",[68],"2012-11","2012-03",[1031],"Beta Thalassemia Intermedia",[1016],{"nctId":1034,"briefTitle":1035,"status":181,"phases":1036,"primaryCompletion":1028,"completion":1037,"start":1038,"enrollment":411,"conditions":1039,"interventions":1040},"NCT01642758","Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon",[68],"2013-01","2012-05",[1031],[1041],"Sodium 2,2 dimethylbutyrate",{"trials":1043,"activeCount":78},[],{"trials":1045,"activeCount":78},[],{"trials":1047,"activeCount":78},[],{"intervention":188,"totalTrials":74,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":78},[],{"trials":1053,"activeCount":78},[],{"trials":1055,"activeCount":78},[1056],{"nctId":179,"briefTitle":180,"status":181,"phases":1057,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":1058,"interventions":1059},[68],[173],[158,188],{"trials":1061,"activeCount":78},[],{"trials":1063,"activeCount":78},[],{"trials":1065,"activeCount":78},[],{"intervention":842,"totalTrials":74,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1069,"activeCount":78},[],{"trials":1071,"activeCount":78},[],{"trials":1073,"activeCount":78},[1074],{"nctId":833,"briefTitle":834,"status":194,"phases":1075,"primaryCompletion":836,"completion":836,"start":837,"enrollment":78,"conditions":1076,"interventions":1077},[68],[839],[841,842],{"trials":1079,"activeCount":78},[],{"trials":1081,"activeCount":78},[],{"trials":1083,"activeCount":78},[],{"intervention":1085,"totalTrials":74,"cells":1086},"Caffeinated Alcoholic Beer",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1088,"activeCount":78},[],{"trials":1090,"activeCount":78},[],{"trials":1092,"activeCount":78},[1093],{"nctId":1094,"briefTitle":1095,"status":181,"phases":1096,"primaryCompletion":815,"completion":815,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1103},"NCT00515294","Acute and Residual Effects of Caffeinated Beer",[67,68],"2006-10",154,[1100,1101,1102],"Neurobehavioral Manifestations","Drug Related Sleep Disturbance","Alcohol Intoxication",[1085,1104],"Caffeinated Non-Alcoholic Beer",{"trials":1106,"activeCount":78},[],{"trials":1108,"activeCount":78},[],{"trials":1110,"activeCount":78},[],{"intervention":1104,"totalTrials":74,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1114,"activeCount":78},[],{"trials":1116,"activeCount":78},[],{"trials":1118,"activeCount":78},[1119],{"nctId":1094,"briefTitle":1095,"status":181,"phases":1120,"primaryCompletion":815,"completion":815,"start":1097,"enrollment":1098,"conditions":1121,"interventions":1122},[67,68],[1100,1101,1102],[1085,1104],{"trials":1124,"activeCount":78},[],{"trials":1126,"activeCount":78},[],{"trials":1128,"activeCount":78},[],{"intervention":1130,"totalTrials":74,"cells":1131},"citalopram hydrobromide",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1133,"activeCount":78},[],{"trials":1135,"activeCount":78},[],{"trials":1137,"activeCount":78},[1138],{"nctId":1139,"briefTitle":1140,"status":181,"phases":1141,"primaryCompletion":1097,"completion":1142,"start":1143,"enrollment":1144,"conditions":1145,"interventions":1147},"NCT00086645","Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)",[68],"2007-04","2004-04",149,[1146],"Autistic Disorder",[1130],{"trials":1149,"activeCount":78},[],{"trials":1151,"activeCount":78},[],{"trials":1153,"activeCount":78},[],{"intervention":1155,"totalTrials":74,"cells":1156},"250 mg DCS",{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1158,"activeCount":78},[],{"trials":1160,"activeCount":78},[],{"trials":1162,"activeCount":78},[1163],{"nctId":1164,"briefTitle":1165,"status":181,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1173},"NCT02376257","Improving Therapeutic Learning in Depression: Proof of Concept",[68],"2017-04-21","2017-05","2014-09-16",36,[1172],"Major Depressive Disorder",[1155,1174],"100 mg Modafinil",{"trials":1176,"activeCount":78},[],{"trials":1178,"activeCount":78},[],{"trials":1180,"activeCount":78},[],{"intervention":1174,"totalTrials":74,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1184,"activeCount":78},[],{"trials":1186,"activeCount":78},[],{"trials":1188,"activeCount":78},[1189],{"nctId":1164,"briefTitle":1165,"status":181,"phases":1190,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1191,"interventions":1192},[68],[1172],[1155,1174],{"trials":1194,"activeCount":78},[],{"trials":1196,"activeCount":78},[],{"trials":1198,"activeCount":78},[],{"intervention":1200,"totalTrials":74,"cells":1201},"Alcohol",{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1218,"PHASE4":1220,"NA":1222},{"trials":1203,"activeCount":78},[],{"trials":1205,"activeCount":78},[],{"trials":1207,"activeCount":78},[1208],{"nctId":1209,"briefTitle":1210,"status":181,"phases":1211,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1217},"NCT00183170","Residual Effects of Intoxication on Student Performance",[68],"2009-01","2004-02",239,[1216,1100],"Alcoholic Intoxication",[1200],{"trials":1219,"activeCount":78},[],{"trials":1221,"activeCount":78},[],{"trials":1223,"activeCount":78},[],{"intervention":1225,"totalTrials":74,"cells":1226},"macitentan",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1228,"activeCount":78},[],{"trials":1230,"activeCount":78},[],{"trials":1232,"activeCount":78},[1233],{"nctId":1234,"briefTitle":1235,"status":669,"phases":1236,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":673,"conditions":1239,"interventions":1241},"NCT02651272","Macitentan in Pulmonary Hypertension of Sickle Cell Disease",[68],"2019-12-18","2015-07",[748,1240],"Sickle Cell Disease",[1225],{"trials":1243,"activeCount":78},[],{"trials":1245,"activeCount":78},[],{"trials":1247,"activeCount":78},[],{"intervention":1249,"totalTrials":74,"cells":1250},"Scopolamine",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1252,"activeCount":78},[],{"trials":1254,"activeCount":78},[],{"trials":1256,"activeCount":78},[1257],{"nctId":1258,"briefTitle":1259,"status":181,"phases":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT00374478","Effects of Transdermal Scopolamine on Occupational Performance",[68],"2006-04","2005-04",33,[1265],"Motion Sickness",[1249],{"trials":1268,"activeCount":78},[],{"trials":1270,"activeCount":78},[],{"trials":1272,"activeCount":78},[],{"intervention":1274,"totalTrials":74,"cells":1275},"AndroGel",{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1291,"PHASE4":1293,"NA":1295},{"trials":1277,"activeCount":78},[],{"trials":1279,"activeCount":78},[],{"trials":1281,"activeCount":78},[1282],{"nctId":1283,"briefTitle":1284,"status":181,"phases":1285,"primaryCompletion":1028,"completion":1028,"start":1261,"enrollment":1286,"conditions":1287,"interventions":1290},"NCT00351819","Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception",[68],84,[1288,1289],"Pain","Hypogonadism",[1274],{"trials":1292,"activeCount":78},[],{"trials":1294,"activeCount":78},[],{"trials":1296,"activeCount":78},[],{"intervention":1298,"totalTrials":74,"cells":1299},"bexarotene",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1301,"activeCount":78},[],{"trials":1303,"activeCount":78},[],{"trials":1305,"activeCount":78},[1306],{"nctId":1307,"briefTitle":1308,"status":181,"phases":1309,"completion":1143,"start":1310,"enrollment":1311,"conditions":1312,"interventions":1314},"NCT00306969","Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma",[67,68],"2001-12",18,[1313],"Cutaneous T-Cell Lymphoma",[1298],{"trials":1316,"activeCount":78},[],{"trials":1318,"activeCount":78},[],{"trials":1320,"activeCount":78},[],{"intervention":1322,"totalTrials":74,"cells":1323},"Rilonacept",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1325,"activeCount":78},[],{"trials":1327,"activeCount":78},[],{"trials":1329,"activeCount":78},[1330],{"nctId":1331,"briefTitle":1332,"status":181,"phases":1333,"primaryCompletion":1334,"completion":1335,"start":902,"enrollment":17,"conditions":1336,"interventions":1341},"NCT01538719","IL1-TRAP, Rilonacept, in Systemic Sclerosis",[67,68],"2017-01","2017-08-11",[1337,1338,1339,1340],"Scleroderma","Systemic Sclerosis","Diffuse Scleroderma","Diffuse Systemic Sclerosis",[1322],{"trials":1343,"activeCount":78},[],{"trials":1345,"activeCount":78},[],{"trials":1347,"activeCount":78},[],{"intervention":1349,"totalTrials":74,"cells":1350},"arginine butyrate",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1352,"activeCount":78},[],{"trials":1354,"activeCount":78},[],{"trials":1356,"activeCount":78},[1357],{"nctId":1358,"briefTitle":1359,"status":181,"phases":1360,"start":1361,"enrollment":881,"conditions":1362,"interventions":1364},"NCT00006136","Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia",[68],"1999-03",[1363],"Beta-Thalassemia",[1349,1365],"epoetin alfa",{"trials":1367,"activeCount":78},[],{"trials":1369,"activeCount":78},[],{"trials":1371,"activeCount":78},[],{"intervention":1365,"totalTrials":74,"cells":1373},{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1375,"activeCount":78},[],{"trials":1377,"activeCount":78},[],{"trials":1379,"activeCount":78},[1380],{"nctId":1358,"briefTitle":1359,"status":181,"phases":1381,"start":1361,"enrollment":881,"conditions":1382,"interventions":1383},[68],[1363],[1349,1365],{"trials":1385,"activeCount":78},[],{"trials":1387,"activeCount":78},[],{"trials":1389,"activeCount":78},[],{"intervention":1391,"totalTrials":74,"cells":1392},"PK-1 Good Manufacturing Practices (GMP) allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1394,"activeCount":78},[],{"trials":1396,"activeCount":78},[],{"trials":1398,"activeCount":78},[1399],{"nctId":1400,"briefTitle":1401,"status":669,"phases":1402,"primaryCompletion":1403,"completion":1403,"start":1404,"enrollment":10,"conditions":1405,"interventions":1408},"NCT04468360","Pharmacokinetic Study for IV Allopregnanolone",[68],"2025-04-29","2022-03-04",[1406,1407],"Pharmacokinetic Study","Post Traumatic Stress Disorder",[1391,1409],"PK-2 GMP allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis.",{"trials":1411,"activeCount":78},[],{"trials":1413,"activeCount":78},[],{"trials":1415,"activeCount":78},[],{"intervention":1409,"totalTrials":74,"cells":1417},{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1419,"activeCount":78},[],{"trials":1421,"activeCount":78},[],{"trials":1423,"activeCount":78},[1424],{"nctId":1400,"briefTitle":1401,"status":669,"phases":1425,"primaryCompletion":1403,"completion":1403,"start":1404,"enrollment":10,"conditions":1426,"interventions":1427},[68],[1406,1407],[1391,1409],{"trials":1429,"activeCount":78},[],{"trials":1431,"activeCount":78},[],{"trials":1433,"activeCount":78},[],{"intervention":1435,"totalTrials":74,"cells":1436},"Mirtazapine",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1438,"activeCount":78},[],{"trials":1440,"activeCount":78},[],{"trials":1442,"activeCount":78},[1443],{"nctId":1444,"briefTitle":1445,"status":181,"phases":1446,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":17,"conditions":1450,"interventions":1452},"NCT00322309","Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects",[68],"2009-07","2010-02","2005-09",[1451,19],"Cocaine Dependence",[1435],{"trials":1454,"activeCount":78},[],{"trials":1456,"activeCount":78},[],{"trials":1458,"activeCount":78},[],{"intervention":863,"totalTrials":74,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1462,"activeCount":78},[],{"trials":1464,"activeCount":78},[],{"trials":1466,"activeCount":78},[1467],{"nctId":853,"briefTitle":854,"status":855,"phases":1468,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":1469,"interventions":1470},[68],[861],[823,863],{"trials":1472,"activeCount":78},[],{"trials":1474,"activeCount":78},[],{"trials":1476,"activeCount":78},[],{"intervention":1478,"totalTrials":74,"cells":1479},"Doxycycline 100 mg po bid x 12 months",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1481,"activeCount":78},[],{"trials":1483,"activeCount":78},[],{"trials":1485,"activeCount":78},[1486],{"nctId":1487,"briefTitle":1488,"status":181,"phases":1489,"primaryCompletion":1490,"completion":1491,"start":1492,"enrollment":1493,"conditions":1494,"interventions":1496},"NCT01677286","Safety and Effect of Doxycycline in Patients With Amyloidosis",[68],"2015-05-22","2015-12-15","2012-07",25,[1495],"Amyloidosis",[1478],{"trials":1498,"activeCount":78},[],{"trials":1500,"activeCount":78},[],{"trials":1502,"activeCount":78},[],{"intervention":1504,"totalTrials":74,"cells":1505},"Celebrex",{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1507,"activeCount":78},[],{"trials":1509,"activeCount":78},[],{"trials":1511,"activeCount":78},[1512],{"nctId":1513,"briefTitle":1514,"status":669,"phases":1515,"primaryCompletion":1447,"completion":1447,"start":1516,"enrollment":411,"conditions":1517,"interventions":1519},"NCT00592319","Celebrex (Celecoxib) Treatment of Laryngeal Papilloma",[68],"2005-05",[1518],"Laryngeal Papilloma",[1504],{"trials":1521,"activeCount":78},[],{"trials":1523,"activeCount":78},[],{"trials":1525,"activeCount":78},[],{"intervention":1527,"totalTrials":74,"cells":1528},"Omega-3-acid ethyl esters",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1542,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1530,"activeCount":78},[],{"trials":1532,"activeCount":78},[1533],{"nctId":1534,"briefTitle":1535,"status":669,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":409,"enrollment":159,"conditions":1538,"interventions":1541},"NCT00694746","Study of Fish Oil to Reduce ALT Levels in Adolescents",[67],"2014-03",[1539,1540],"Non-alcoholic Fatty Liver Disease","Fatty Liver",[1527],{"trials":1543,"activeCount":78},[],{"trials":1545,"activeCount":78},[],{"trials":1547,"activeCount":78},[],{"trials":1549,"activeCount":78},[],{"intervention":1551,"totalTrials":74,"cells":1552},"ascorbic acid",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1568,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1554,"activeCount":78},[],{"trials":1556,"activeCount":78},[1557],{"nctId":1558,"briefTitle":1559,"status":669,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1566},"NCT00491751","Clinical Utility of Endothelial Dysfunction in PAD",[67],"2012-06","2004-05",108,[1565],"Peripheral Arterial Disease",[1567,1551],"atorvastatin",{"trials":1569,"activeCount":78},[],{"trials":1571,"activeCount":78},[],{"trials":1573,"activeCount":78},[],{"trials":1575,"activeCount":78},[],{"intervention":1577,"totalTrials":74,"cells":1578},"Mycophenolate Mofetil",{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1593,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1580,"activeCount":78},[],{"trials":1582,"activeCount":78},[1583],{"nctId":1584,"briefTitle":1585,"status":181,"phases":1586,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1592},"NCT00433186","Mycophenolate Mofetil in Systemic Sclerosis",[67],"2011-03","2006-03",30,[1591],"Diffuse Cutaneous Systemic Sclerosis",[1577],{"trials":1594,"activeCount":78},[],{"trials":1596,"activeCount":78},[],{"trials":1598,"activeCount":78},[],{"trials":1600,"activeCount":78},[],{"intervention":1602,"totalTrials":74,"cells":1603},"Fresolimumab",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1605,"activeCount":78},[],{"trials":1607,"activeCount":78},[1608],{"nctId":1609,"briefTitle":1610,"status":181,"phases":1611,"primaryCompletion":1612,"completion":1537,"start":1613,"enrollment":1311,"conditions":1614,"interventions":1615},"NCT01284322","Fresolimumab In Systemic Sclerosis",[67],"2013-06","2011-01",[1340],[1602],{"trials":1617,"activeCount":78},[],{"trials":1619,"activeCount":78},[],{"trials":1621,"activeCount":78},[],{"trials":1623,"activeCount":78},[],{"intervention":1625,"totalTrials":74,"cells":1626},"salsalate",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1642,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1628,"activeCount":78},[],{"trials":1630,"activeCount":78},[1631],{"nctId":1632,"briefTitle":1633,"status":181,"phases":1634,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1641},"NCT00553995","Effect of Salsalate on Bed Rest-Induced Vascular Dysfunction",[67],"2013-12-01","2014-12-01","2008-05",60,[1640],"Insulin Resistance",[1625],{"trials":1643,"activeCount":78},[],{"trials":1645,"activeCount":78},[],{"trials":1647,"activeCount":78},[],{"trials":1649,"activeCount":78},[],{"intervention":1651,"totalTrials":74,"cells":1652},"vitamin D3",{"EARLY_PHASE1":1653,"PHASE1":1666,"PHASE2":1668,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1654,"activeCount":78},[1655],{"nctId":1656,"briefTitle":1657,"status":181,"phases":1658,"primaryCompletion":1659,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1665},"NCT00779909","Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model",[66],"2011-05","2011-09","2008-12",35,[1664],"Gingivitis",[1651],{"trials":1667,"activeCount":78},[],{"trials":1669,"activeCount":78},[],{"trials":1671,"activeCount":78},[],{"trials":1673,"activeCount":78},[],{"trials":1675,"activeCount":78},[],{"intervention":1677,"totalTrials":74,"cells":1678},"Tolcapone",{"EARLY_PHASE1":1679,"PHASE1":1691,"PHASE2":1693,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1680,"activeCount":78},[1681],{"nctId":1682,"briefTitle":1683,"status":181,"phases":1684,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":411,"conditions":1687,"interventions":1690},"NCT03591757","Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)",[66],"2019-04-26","2018-10-30",[1688,1689],"Transthyretin Amyloidosis","Amyloidosis, Leptomeningeal, Transthyretin-Related",[1677],{"trials":1692,"activeCount":78},[],{"trials":1694,"activeCount":78},[],{"trials":1696,"activeCount":78},[],{"trials":1698,"activeCount":78},[],{"trials":1700,"activeCount":78},[],{"intervention":1702,"totalTrials":74,"cells":1703},"Calcifediol",{"EARLY_PHASE1":1704,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1705,"activeCount":78},[1706],{"nctId":1707,"briefTitle":1708,"status":181,"phases":1709,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":1713,"conditions":1714,"interventions":1716},"NCT03401541","25-Hydroxyvitamin D Pharmacokinetic Study",[66],"2019-04-01","2019-11-01","2018-10-01",16,[28,1715],"Fat Malabsorption",[1702,1717],"Calciferol",{"trials":1719,"activeCount":78},[],{"trials":1721,"activeCount":78},[],{"trials":1723,"activeCount":78},[],{"trials":1725,"activeCount":78},[],{"trials":1727,"activeCount":78},[],{"intervention":1717,"totalTrials":74,"cells":1729},{"EARLY_PHASE1":1730,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1731,"activeCount":78},[1732],{"nctId":1707,"briefTitle":1708,"status":181,"phases":1733,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":1713,"conditions":1734,"interventions":1735},[66],[28,1715],[1702,1717],{"trials":1737,"activeCount":78},[],{"trials":1739,"activeCount":78},[],{"trials":1741,"activeCount":78},[],{"trials":1743,"activeCount":78},[],{"trials":1745,"activeCount":78},[],{"intervention":1747,"totalTrials":74,"cells":1748},"Metformin",{"EARLY_PHASE1":1749,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1750,"activeCount":78},[1751],{"nctId":1752,"briefTitle":1753,"status":181,"phases":1754,"primaryCompletion":1755,"completion":1756,"start":1449,"enrollment":1757,"conditions":1758,"interventions":1760},"NCT01037660","Effects of Lipemia and Metformin on Endothelial Function",[66],"2015-12-01","2016-12-01",139,[1759],"Cardiovascular Disease",[1747],{"trials":1762,"activeCount":78},[],{"trials":1764,"activeCount":78},[],{"trials":1766,"activeCount":78},[],{"trials":1768,"activeCount":78},[],{"trials":1770,"activeCount":78},[],{"intervention":1772,"totalTrials":159,"cells":1773},"Zonisamide",{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1787,"PHASE4":1798,"NA":1800},{"trials":1775,"activeCount":78},[],{"trials":1777,"activeCount":78},[],{"trials":1779,"activeCount":78},[1780],{"nctId":1781,"briefTitle":1782,"status":181,"phases":1783,"primaryCompletion":848,"completion":1784,"start":564,"enrollment":1713,"conditions":1785,"interventions":1786},"NCT00406692","The Effects of Zonisamide on Alcohol Dependence",[68],"2009-11",[413],[1772],{"trials":1788,"activeCount":78},[1789],{"nctId":1790,"briefTitle":1791,"status":181,"phases":1792,"primaryCompletion":1793,"completion":1793,"start":1794,"enrollment":1795,"conditions":1796,"interventions":1797},"NCT02901041","Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism",[69],"2022-01-04","2017-09-21",81,[703],[1772],{"trials":1799,"activeCount":78},[],{"trials":1801,"activeCount":78},[1802],{"nctId":1803,"briefTitle":1804,"status":181,"phases":1805,"primaryCompletion":1806,"completion":1807,"start":564,"enrollment":411,"conditions":1808,"interventions":1809},"NCT00398918","Alcohol Self Administration Laboratory",[71],"2007-10","2009-03",[413],[1810],"zonisamide",{"intervention":1567,"totalTrials":209,"cells":1812},{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1814,"activeCount":78},[],{"trials":1816,"activeCount":78},[1817],{"nctId":1558,"briefTitle":1559,"status":669,"phases":1818,"primaryCompletion":1561,"completion":1561,"start":1562,"enrollment":1563,"conditions":1819,"interventions":1820},[67],[1565],[1567,1551],{"trials":1822,"activeCount":78},[],{"trials":1824,"activeCount":78},[],{"trials":1826,"activeCount":78},[],{"trials":1828,"activeCount":78},[1829],{"nctId":1830,"briefTitle":1831,"status":669,"phases":1832,"primaryCompletion":1661,"completion":1661,"start":1449,"enrollment":1833,"conditions":1834,"interventions":1837},"NCT00491400","Effect of a Fibrate and a Statin on Endothelial Dysfunction",[71],28,[1835,1836],"Diabetes Mellitus","Metabolic Syndrome",[1838,1839],"Fenofibrate","Atorvastatin",{"intervention":1841,"totalTrials":209,"cells":1842},"Chlorhexidine gluconate",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1861,"NA":1863},{"trials":1844,"activeCount":78},[],{"trials":1846,"activeCount":78},[],{"trials":1848,"activeCount":78},[],{"trials":1850,"activeCount":78},[1851],{"nctId":1852,"briefTitle":1853,"status":181,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1860},"NCT01241318","Zambia Chlorhexidine Application Trial",[68,69],"2013-09","2011-02",77535,[1859],"Sepsis",[1841],{"trials":1862,"activeCount":78},[],{"trials":1864,"activeCount":78},[1865],{"nctId":1866,"briefTitle":1867,"status":181,"phases":1868,"primaryCompletion":1869,"completion":1870,"start":1871,"enrollment":1872,"conditions":1873,"interventions":1876},"NCT02386592","Prevention of Nosocomial Bacteremia Among Zambian Neonates",[71],"2017-04-15","2017-07","2015-09-01",9410,[1874,1875],"Neonatal Sepsis","Neonatal Mortality",[1841],{"intervention":1878,"totalTrials":209,"cells":1879},"Misoprostol",{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1886,"PHASE4":1897,"NA":1899},{"trials":1881,"activeCount":78},[],{"trials":1883,"activeCount":78},[],{"trials":1885,"activeCount":78},[],{"trials":1887,"activeCount":78},[1888],{"nctId":1889,"briefTitle":1890,"status":669,"phases":1891,"primaryCompletion":1892,"completion":1892,"start":746,"enrollment":159,"conditions":1893,"interventions":1896},"NCT01436266","Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion",[69],"2012-08",[1894,1895],"Abortion","Blood Loss",[1878],{"trials":1898,"activeCount":78},[],{"trials":1900,"activeCount":78},[1901],{"nctId":1902,"briefTitle":1903,"status":669,"phases":1904,"primaryCompletion":745,"completion":745,"start":1561,"enrollment":1905,"conditions":1906,"interventions":1910},"NCT01636063","Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks",[71],42,[1907,1908,1909,1878],"Induced Abortion","Abortion Techniques","Mifepristone",[1909,1878],{"intervention":1909,"totalTrials":209,"cells":1912},{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1930,"NA":1932},{"trials":1914,"activeCount":78},[],{"trials":1916,"activeCount":78},[],{"trials":1918,"activeCount":78},[],{"trials":1920,"activeCount":78},[1921],{"nctId":1922,"briefTitle":1923,"status":181,"phases":1924,"primaryCompletion":1925,"completion":1925,"start":746,"enrollment":1926,"conditions":1927,"interventions":1929},"NCT01436279","Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks",[69],"2013-08",50,[1928],"Cervical Preparation",[1909],{"trials":1931,"activeCount":78},[],{"trials":1933,"activeCount":78},[1934],{"nctId":1902,"briefTitle":1903,"status":669,"phases":1935,"primaryCompletion":745,"completion":745,"start":1561,"enrollment":1905,"conditions":1936,"interventions":1937},[71],[1907,1908,1909,1878],[1909,1878],{"intervention":1939,"totalTrials":74,"cells":1940},"Genetic",{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1942,"activeCount":78},[],{"trials":1944,"activeCount":78},[],{"trials":1946,"activeCount":78},[],{"trials":1948,"activeCount":78},[],{"trials":1950,"activeCount":78},[],{"trials":1952,"activeCount":78},[1953],{"nctId":1954,"briefTitle":1955,"status":181,"phases":1956,"primaryCompletion":1855,"completion":1855,"start":1660,"enrollment":1957,"conditions":1958,"interventions":1960},"NCT01355224","Communicating Risk Information for Obesity",[71],798,[1959],"Obesity",[1939],{"intervention":1962,"totalTrials":74,"cells":1963},"Coartem and amoxicillin",{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1970,"PHASE4":1972,"NA":1974},{"trials":1965,"activeCount":78},[],{"trials":1967,"activeCount":78},[],{"trials":1969,"activeCount":78},[],{"trials":1971,"activeCount":78},[],{"trials":1973,"activeCount":78},[],{"trials":1975,"activeCount":78},[1976],{"nctId":1977,"briefTitle":1978,"status":181,"phases":1979,"primaryCompletion":1980,"completion":1981,"start":1982,"enrollment":1983,"conditions":1984,"interventions":1987},"NCT00513500","Zambia Integrated Management of Malaria and Pneumonia Study",[71],"2009-02","2009-09","2007-06",3125,[1985,1986],"Pneumonia","Malaria",[1962,1988],"Coartem",{"intervention":1988,"totalTrials":74,"cells":1990},{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":1997,"PHASE4":1999,"NA":2001},{"trials":1992,"activeCount":78},[],{"trials":1994,"activeCount":78},[],{"trials":1996,"activeCount":78},[],{"trials":1998,"activeCount":78},[],{"trials":2000,"activeCount":78},[],{"trials":2002,"activeCount":78},[2003],{"nctId":1977,"briefTitle":1978,"status":181,"phases":2004,"primaryCompletion":1980,"completion":1981,"start":1982,"enrollment":1983,"conditions":2005,"interventions":2006},[71],[1985,1986],[1962,1988],{"intervention":1838,"totalTrials":74,"cells":2008},{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2019},{"trials":2010,"activeCount":78},[],{"trials":2012,"activeCount":78},[],{"trials":2014,"activeCount":78},[],{"trials":2016,"activeCount":78},[],{"trials":2018,"activeCount":78},[],{"trials":2020,"activeCount":78},[2021],{"nctId":1830,"briefTitle":1831,"status":669,"phases":2022,"primaryCompletion":1661,"completion":1661,"start":1449,"enrollment":1833,"conditions":2023,"interventions":2024},[71],[1835,1836],[1838,1839],{"intervention":2026,"totalTrials":74,"cells":2027},"Sulfasalazine",{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2032,"PHASE3":2034,"PHASE4":2036,"NA":2038},{"trials":2029,"activeCount":78},[],{"trials":2031,"activeCount":78},[],{"trials":2033,"activeCount":78},[],{"trials":2035,"activeCount":78},[],{"trials":2037,"activeCount":78},[],{"trials":2039,"activeCount":78},[2040],{"nctId":2041,"briefTitle":2042,"status":181,"phases":2043,"primaryCompletion":903,"completion":903,"start":2044,"enrollment":1638,"conditions":2045,"interventions":2047},"NCT00554203","Sulfasalazine and Endothelial Function",[71],"2003-07",[2046],"Coronary Artery Disease",[2026],{"intervention":2049,"totalTrials":74,"cells":2050},"Topical anesthetic gel",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2052,"activeCount":78},[],{"trials":2054,"activeCount":78},[],{"trials":2056,"activeCount":78},[],{"trials":2058,"activeCount":78},[],{"trials":2060,"activeCount":78},[],{"trials":2062,"activeCount":78},[2063],{"nctId":2064,"briefTitle":2065,"status":194,"phases":2066,"primaryCompletion":2067,"completion":2068,"start":2069,"enrollment":78,"conditions":2070,"interventions":2074},"NCT03779659","Effectiveness of Synapse Transcutaneous Electronic Nerve Stimulation (TENS) During Dental Procedures Among Children",[71],"2022-12","2023-02","2021-07",[2071,2072,2073],"Dental Fear","Anesthesia, Local","Pediatric Dentistry",[2049],{"intervention":2076,"totalTrials":74,"cells":2077},"Addition of misoprostol 25 mcg 12 hours before induction",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2079,"activeCount":78},[],{"trials":2081,"activeCount":78},[],{"trials":2083,"activeCount":78},[],{"trials":2085,"activeCount":78},[],{"trials":2087,"activeCount":78},[],{"trials":2089,"activeCount":78},[2090],{"nctId":2091,"briefTitle":2092,"status":181,"phases":2093,"primaryCompletion":2094,"completion":2094,"start":814,"enrollment":1493,"conditions":2095,"interventions":2098},"NCT00495560","A Pilot Study of Priming Before Induction Termination of Pregnancy",[71],"2007-07",[2096,2097],"Abortion, Induced","Abortion, Second Trimester",[2076],{"intervention":2100,"totalTrials":74,"cells":2101},"Addition of mifepristone 200 mg 24 hours before induction",{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2103,"activeCount":78},[],{"trials":2105,"activeCount":78},[],{"trials":2107,"activeCount":78},[],{"trials":2109,"activeCount":78},[],{"trials":2111,"activeCount":78},[],{"trials":2113,"activeCount":78},[2114],{"nctId":2115,"briefTitle":2116,"status":181,"phases":2117,"primaryCompletion":564,"completion":564,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2121},"NCT00382538","Mifepristone and Mid-Trimester Termination of Pregnancy",[71],"2005-03",64,[2096,2097],[2100],{"intervention":2123,"totalTrials":74,"cells":2124},"mifepristone 200 mg",{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2131,"PHASE4":2133,"NA":2135},{"trials":2126,"activeCount":78},[],{"trials":2128,"activeCount":78},[],{"trials":2130,"activeCount":78},[],{"trials":2132,"activeCount":78},[],{"trials":2134,"activeCount":78},[],{"trials":2136,"activeCount":78},[2137],{"nctId":2138,"briefTitle":2139,"status":181,"phases":2140,"primaryCompletion":1587,"completion":1587,"start":815,"enrollment":1926,"conditions":2141,"interventions":2142},"NCT00986921","Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks",[71],[1894],[2123],{"intervention":2144,"totalTrials":74,"cells":2145},"N-acetylcysteine",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2152,"PHASE4":2154,"NA":2156},{"trials":2147,"activeCount":78},[],{"trials":2149,"activeCount":78},[],{"trials":2151,"activeCount":78},[],{"trials":2153,"activeCount":78},[],{"trials":2155,"activeCount":78},[],{"trials":2157,"activeCount":78},[2158],{"nctId":2159,"briefTitle":2160,"status":181,"phases":2161,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":772,"conditions":2165,"interventions":2166},"NCT01037465","ROS Signaling in Endothelial Function",[71],"2015-12","2016-03-26","2008-09",[1759],[2144],{"intervention":2168,"totalTrials":74,"cells":2169},"Misoprostol and placebo",{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2176,"PHASE4":2178,"NA":2180},{"trials":2171,"activeCount":78},[],{"trials":2173,"activeCount":78},[],{"trials":2175,"activeCount":78},[],{"trials":2177,"activeCount":78},[],{"trials":2179,"activeCount":78},[],{"trials":2181,"activeCount":78},[2182],{"nctId":2183,"briefTitle":2184,"status":669,"phases":2185,"primaryCompletion":1661,"completion":1661,"start":1142,"enrollment":1713,"conditions":2186,"interventions":2191},"NCT00468299","MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure",[71],[2187,2188,2189,2190],"Early Pregnancy Failure","Miscarriage","Fetal Demise","Anembryonic Pregnancy",[2168,2192],"Mifepristone and misoprostol",{"intervention":2192,"totalTrials":74,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2201,"PHASE4":2203,"NA":2205},{"trials":2196,"activeCount":78},[],{"trials":2198,"activeCount":78},[],{"trials":2200,"activeCount":78},[],{"trials":2202,"activeCount":78},[],{"trials":2204,"activeCount":78},[],{"trials":2206,"activeCount":78},[2207],{"nctId":2183,"briefTitle":2184,"status":669,"phases":2208,"primaryCompletion":1661,"completion":1661,"start":1142,"enrollment":1713,"conditions":2209,"interventions":2210},[71],[2187,2188,2189,2190],[2168,2192],{"intervention":2212,"totalTrials":74,"cells":2213},"DMPA",{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2218,"PHASE3":2220,"PHASE4":2222,"NA":2224},{"trials":2215,"activeCount":78},[],{"trials":2217,"activeCount":78},[],{"trials":2219,"activeCount":78},[],{"trials":2221,"activeCount":78},[],{"trials":2223,"activeCount":78},[],{"trials":2225,"activeCount":78},[2226],{"nctId":2227,"briefTitle":2228,"status":181,"phases":2229,"primaryCompletion":2230,"completion":2230,"start":1659,"enrollment":817,"conditions":2231,"interventions":2233},"NCT01356927","Same-day Long-acting Reversible Contraception for Medication Abortion",[],"2014-04",[2232],"Abortion; Induced",[2212,2234],"Etonogestrel implant",{"intervention":2234,"totalTrials":74,"cells":2236},{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2238,"activeCount":78},[],{"trials":2240,"activeCount":78},[],{"trials":2242,"activeCount":78},[],{"trials":2244,"activeCount":78},[],{"trials":2246,"activeCount":78},[],{"trials":2248,"activeCount":78},[2249],{"nctId":2227,"briefTitle":2228,"status":181,"phases":2250,"primaryCompletion":2230,"completion":2230,"start":1659,"enrollment":817,"conditions":2251,"interventions":2252},[],[2232],[2212,2234]]